These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 26306819)

  • 41. Defining "Adequately Treated": A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate.
    O'Donnell A; Rao S; Turkoz I; Gopal S; Kim E
    Neuropsychiatr Dis Treat; 2021; 17():1-9. PubMed ID: 33442251
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain.
    Gutiérrez-Rojas L; Sánchez-Alonso S; García Dorado M; López Rengel PM
    CNS Drugs; 2022 May; 36(5):517-527. PubMed ID: 35460508
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies.
    Mathews M; Gopal S; Singh A; Nuamah I; Pungor K; Tan W; Soares B; Kim E; Savitz AJ
    Neuropsychiatr Dis Treat; 2020; 16():1533-1542. PubMed ID: 32606705
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Paliperidone Palmitate Intramuscular 3-Monthly Formulation: A Review in Schizophrenia.
    Lamb YN; Keating GM
    Drugs; 2016 Oct; 76(16):1559-1566. PubMed ID: 27699643
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia.
    Magnusson MO; Samtani MN; Plan EL; Jonsson EN; Rossenu S; Vermeulen A; Russu A
    Clin Pharmacokinet; 2017 Apr; 56(4):421-433. PubMed ID: 27743205
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Switch From Paliperidone Long-Acting Injectable 1- to 3-Monthly: Clinical Pharmacokinetic Evaluation in Patients With Schizophrenia (Preliminary Data).
    Mauri MC; Franco G; Minutillo A; Paletta S; Di Pace C; Reggiori A; Baldelli S; Cattaneo D
    J Clin Psychopharmacol; 2022 Jan-Feb 01; 42(1):23-30. PubMed ID: 34840286
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of paliperidone palmitate 6-monthly long-acting injectable in reduction of relapses in patients with schizophrenia: An Asian subgroup analysis of phase 3, randomized study.
    Richarz U; Han J; Bai YM; Yu-Hai Chen E; Chung YC; Jhanwar VG; Kim SW; Sulaiman AH; Knight K; Gopal S
    Medicine (Baltimore); 2023 Aug; 102(34):e34623. PubMed ID: 37653768
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia.
    Rossenu S; Cleton A; Hough D; Crauwels H; Vandebosch A; Berwaerts J; Eerdekens M; Herben V; De Meulder M; Remmerie B; Francetic I
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):270-8. PubMed ID: 27136907
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study.
    Gopal S; Gogate J; Pungor K; Kim E; Singh A; Mathews M
    Neuropsychiatr Dis Treat; 2020; 16():681-690. PubMed ID: 32184607
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Need for Bioequivalence Standards that Reflect the Clinical Importance of the Complex Pharmacokinetics of Paliperidone Palmitate Long-Acting Injectable Suspension.
    Procyshyn RM; Lamoure JW; Katzman MA; Skinner PL; Sherman SE
    J Pharm Pharm Sci; 2019; 22(1):548-566. PubMed ID: 31730504
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of paliperidone palmitate long-acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia.
    Brown B; Turkoz I; Mancevski B; Mathews M
    Early Interv Psychiatry; 2020 Aug; 14(4):428-438. PubMed ID: 31515972
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Paliperidone 3-Month Injection for Treatment of Schizophrenia: A Narrative Review.
    Edinoff AN; Doppalapudi PK; Orellana C; Ochoa C; Patti S; Ghaffar Y; Cornett EM; Kaye AJ; Viswanath O; Urits I; Kaye AM; Kaye AD
    Front Psychiatry; 2021; 12():699748. PubMed ID: 34621193
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population.
    Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Hough D; Hargarter L
    Neuropsychiatr Dis Treat; 2019; 15():587-602. PubMed ID: 30863080
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation.
    Dickson MC; Nguyen MM; Patel C; Grabich SC; Benson C; Cothran T; Skrepnek GH
    Adv Ther; 2023 Jan; 40(1):349-366. PubMed ID: 36348142
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle: Are They Therapeutically Equivalent?
    Yin J; Collier AC; Barr AM; Honer WG; Procyshyn RM
    J Clin Psychopharmacol; 2015 Aug; 35(4):447-9. PubMed ID: 26061612
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Patient, Investigator, Nurse, Carer Questionnaire (PINC-Q): a cross-sectional, retrospective, non-interventional study exploring the impact of less frequent medication administration with paliperidone palmitate 3-monthly as maintenance treatment for schizophrenia.
    Pungor K; Sanchez P; Pappa S; Attal J; Leopold K; Steegen G; Vita A; Marsella C; Verrijcken C; Lahaye M; Wooller A
    BMC Psychiatry; 2021 Jun; 21(1):300. PubMed ID: 34107886
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis.
    Li G; Keenan A; Daskiran M; Mathews M; Nuamah I; Orman C; Joshi K; Singh A; Godet A; Pungor K; Gopal S
    Patient Prefer Adherence; 2021; 15():2239-2248. PubMed ID: 34629867
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia.
    Fernández-Miranda JJ; Díaz-Fernández S; De Berardis D; López-Muñoz F
    J Clin Med; 2021 Apr; 10(7):. PubMed ID: 33915786
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice.
    Lopez A; Rey J
    Neuropsychiatr Dis Treat; 2019; 15():449-456. PubMed ID: 30804673
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.
    Berwaerts J; Liu Y; Gopal S; Nuamah I; Xu H; Savitz A; Coppola D; Schotte A; Remmerie B; Maruta N; Hough DW
    JAMA Psychiatry; 2015 Aug; 72(8):830-9. PubMed ID: 25820612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.